ADAM23

Summary

ADAM23 (ADAM metallopeptidase domain 23, HGNC:202) is a protein-coding gene on chromosome 2q33.3, encoding Disintegrin and metalloproteinase domain-containing protein 23 (O75077). May play a role in cell-cell and cell-matrix interactions.

This gene encodes a member of the ADAM (a disintegrin and metalloprotease domain) family. Members of this family are membrane-anchored proteins structurally related to snake venom disintegrins and have been implicated in a variety of biological processes involving cell-cell and cell-matrix interactions, including fertilization, muscle development, and neurogenesis. It is reported that inactivation of this gene is associated with tumorigenesis in human cancers.

Source: NCBI Gene 8745 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 119 total — 1 pathogenic, 1 likely-pathogenic
• MANE Select transcript: NM_003812

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:202
Approved symbol	ADAM23
Name	ADAM metallopeptidase domain 23
Location	2q33.3
Locus type	gene with protein product
Status	Approved
Aliases	MDC3
Ensembl gene	ENSG00000114948
Ensembl biotype	protein_coding
OMIM	603710
Entrez	8745

Gene structure

Transcript identifiers

Ensembl transcripts: 17 — 17 protein_coding

ENST00000264377, ENST00000374415, ENST00000444281, ENST00000860076, ENST00000860077, ENST00000919894, ENST00000919895, ENST00000944276, ENST00000944277, ENST00000944278, ENST00000944279, ENST00000944280, ENST00000944281, ENST00000944282, ENST00000944283, ENST00000944284, ENST00000944285

RefSeq mRNA: 2 — MANE Select: NM_003812 NM_001410985, NM_003812

CCDS: CCDS2369, CCDS92936

Canonical transcript exons

ENST00000264377 — 26 exons

Exon	Start	End
ENSE00000784971	206445307	206445524
ENSE00000784972	206481232	206481308
ENSE00000784973	206530885	206530948
ENSE00000784974	206542052	206542134
ENSE00000784975	206543253	206543316
ENSE00000784976	206547429	206547501
ENSE00000784977	206548281	206548354
ENSE00000784978	206550095	206550160
ENSE00000784979	206557427	206557498
ENSE00000784980	206559955	206560118
ENSE00000784981	206561128	206561212
ENSE00000784982	206562203	206562293
ENSE00000784983	206565020	206565068
ENSE00000784984	206567223	206567322
ENSE00000784985	206570740	206570811
ENSE00000784986	206571727	206571816
ENSE00000784987	206573115	206573195
ENSE00000784991	206592617	206592736
ENSE00000784992	206594737	206594905
ENSE00000784993	206596051	206596162
ENSE00000934666	206587325	206587375
ENSE00000934667	206588091	206588154
ENSE00000934668	206589409	206589514
ENSE00001792196	206617579	206621127
ENSE00001950784	206443532	206444080
ENSE00002400920	206609910	206610000

Expression profiles

Bgee: expression breadth ubiquitous, 225 present calls, max score 94.52.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 8.2418 / max 162.4117, expressed in 1081 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
24829	4.7191	943
24830	2.9827	799
24832	0.2433	112
24833	0.2111	89
24837	0.0856	30

Top tissues by expression

287 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
Brodmann (1909) area 10	UBERON:0013541	94.52	gold quality
middle temporal gyrus	UBERON:0002771	94.16	gold quality
Brodmann (1909) area 23	UBERON:0013554	94.01	gold quality
lateral nuclear group of thalamus	UBERON:0002736	93.34	gold quality
primary visual cortex	UBERON:0002436	92.49	gold quality
prefrontal cortex	UBERON:0000451	91.78	gold quality
postcentral gyrus	UBERON:0002581	91.78	gold quality
cortical plate	UBERON:0005343	91.28	gold quality
superior frontal gyrus	UBERON:0002661	91.06	gold quality
Brodmann (1909) area 9	UBERON:0013540	90.94	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	90.83	gold quality
heart left ventricle	UBERON:0002084	90.79	gold quality
cardiac ventricle	UBERON:0002082	90.65	gold quality
parietal lobe	UBERON:0001872	90.62	gold quality
occipital lobe	UBERON:0002021	90.62	gold quality
nucleus accumbens	UBERON:0001882	90.50	gold quality
frontal cortex	UBERON:0001870	90.44	gold quality
frontal lobe	UBERON:0016525	90.44	gold quality
dorsal root ganglion	UBERON:0000044	90.30	gold quality
neocortex	UBERON:0001950	89.91	gold quality
apex of heart	UBERON:0002098	89.46	gold quality
endothelial cell	CL:0000115	89.42	gold quality
right frontal lobe	UBERON:0002810	88.91	gold quality
Brodmann (1909) area 46	UBERON:0006483	88.81	gold quality
cerebral cortex	UBERON:0000956	88.56	gold quality
caudate nucleus	UBERON:0001873	88.56	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	88.37	gold quality
cingulate cortex	UBERON:0003027	88.13	gold quality
telencephalon	UBERON:0001893	88.08	gold quality
pons	UBERON:0000988	88.04	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-HCAD-35	yes	87.95
E-ANND-3	no	5.69
E-MTAB-9543	no	1.22

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): SP1

miRNA regulators (miRDB)

203 targeting ADAM23, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-4682	100.00	68.89	1258
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-4283	100.00	66.42	2097
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-4776-3P	100.00	68.73	1340
HSA-MIR-29A-3P	100.00	73.11	1835
HSA-MIR-29B-3P	100.00	73.18	1833
HSA-MIR-29C-3P	100.00	73.15	1833
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-33A-5P	99.99	68.62	1055
HSA-MIR-33B-5P	99.99	68.58	1062
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-511-3P	99.99	68.85	1467
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-4789-5P	99.98	70.76	2721
HSA-MIR-103A-3P	99.98	69.14	1595
HSA-MIR-107	99.98	69.14	1595
HSA-MIR-32-5P	99.98	75.21	1964
HSA-MIR-92A-3P	99.98	75.21	1960
HSA-MIR-92B-3P	99.98	75.25	1955
HSA-MIR-25-3P	99.98	74.60	1817
HSA-MIR-363-3P	99.98	74.72	1821
HSA-MIR-367-3P	99.98	74.83	1819
HSA-MIR-548N	99.98	71.94	4170

Literature-anchored findings (GeneRIF, showing 17)

• Together, these results indicate that ADAM23 down-regulation by methylation in brain tumors is a rare event and it may help explain why brain tumor metastases are rarely found elsewhere in the body. (PMID:15862898)
• ADAM23 is frequently silenced in gastric cancers by homozygous deletion or aberrant promoter methylation. (PMID:16103878)
• ADAM23 may be down-regulated by aberrant promoter hypermethylation during the progression of colorectal cancer. (PMID:19089928)
• PrP(C) is a novel molecular partner for ADAM23 in the nervous systems. (PMID:19477226)
• Functional role of ADAM23 during lung caner metastatic progression by negatively modulating alpha(v)beta(3) integrin activation. (PMID:19549921)
• a SP1 binding site (-202/-190) that binds SP1 at the proximal promoter of human ADAM23 gene was indentified. (PMID:20851106)
• The expression level of ADAM23 is likely to be involved in the progression of non-small-cell lung carcinoma, and its downregulation is probably correlated with promoter methylation. (PMID:21429053)
• Intratumoral heterogeneity of ADAM23 promotes tumor growth and metastasis through LGI4 and nitric oxide signals. (PMID:24662834)
• quantification of CXCL12 and ADAM23 methylation could be useful for the prediction of advanced stage of BC (PMID:25620615)
• High ADAM23 gene methylation is associated with gastric tumor aggressiveness. (PMID:25740824)
• Our data provide evidence that ADAM23 plays a role in suppression of cancer cell progression through interaction with aVb3 integrin, and suggest that downregulation of ADAM23 in SP cells may contribute toward providing a cancer stem cell phenotype (PMID:26800504)
• these results support the existence of a second mechanism, alternative to inhibition of protein secretion, by which ADLTE-causing LGI1 mutations exert their loss-of-function effect extracellularly, and suggest that interactions of LGI1 with both ADAM22 and ADAM23 play an important role in the molecular mechanisms leading to utosomal dominant lateral temporal epilepsy (PMID:27760137)
• ADAM23 regulates neuronal differentiation by triggering specific signaling pathways during human neural progenitor cells differentiation. (PMID:28828010)
• Our results demonstrate that ADAM23 expression is likely involved in the progression of epithelial ovarian cancer (PMID:29921495)
• The relationships between the decreased methylation levels of the SNAI2 and ADAM23 genes and cancer de-differentiation and haematogenous dissemination, respectively, indicate novel functions of those genes in the invasive processes. (PMID:30189837)
• Results indicate that ADAM23 is likely involved in breast cancer (BC) progression and dissemination of mesenchymal circulating tumor cells. ADAM23 methylation has the potential to function as a novel prognostic marker. (PMID:30815959)
• Endocytosis of the non-catalytic ADAM23: Recycling and long half-life properties. (PMID:33296662)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	adam23a	ENSDARG00000062323
danio_rerio		ENSDARG00000112453
mus_musculus	Adam23	ENSMUSG00000025964
rattus_norvegicus	Adam23	ENSRNOG00000012424
drosophila_melanogaster	kuz	FBGN0259984
caenorhabditis_elegans	sup-17	WBGENE00006324

Paralogs (20): ADAM22 (ENSG00000008277), ADAM28 (ENSG00000042980), ADAM7 (ENSG00000069206), ADAM11 (ENSG00000073670), ADAM2 (ENSG00000104755), ADAM20 (ENSG00000134007), ADAMDEC1 (ENSG00000134028), ADAM30 (ENSG00000134249), ADAM19 (ENSG00000135074), ADAM10 (ENSG00000137845), ADAM21 (ENSG00000139985), ADAM15 (ENSG00000143537), ADAM12 (ENSG00000148848), ADAM33 (ENSG00000149451), ADAM8 (ENSG00000151651), ADAM17 (ENSG00000151694), ADAM29 (ENSG00000168594), ADAM9 (ENSG00000168615), ADAM18 (ENSG00000168619), ADAM32 (ENSG00000197140)

Protein

Protein identifiers

Disintegrin and metalloproteinase domain-containing protein 23 — O75077 (reviewed: O75077)

Alternative names: Metalloproteinase-like, disintegrin-like, and cysteine-rich protein 3

All UniProt accessions (3): O75077, E7EWD3, H7C2M6

UniProt curated annotations — full annotation on UniProt →

Function. May play a role in cell-cell and cell-matrix interactions. This is a non-catalytic metalloprotease-like protein.

Subunit / interactions. Can bind to LGI1 and LGI4. Ligand for integrin alpha-V/beta-3.

Subcellular location. Cell membrane Secreted.

Tissue specificity. Highly expressed in the brain and weakly expressed in the heart. In the brain, expressed prominently in the amygdala, caudate nucleus, hypothalamus, thalamus, cerebral cortex and occipital pole.

Domain organisation. A conserved motif AVN[ED]CD within the disintegrin-like domain could be involved in the binding to the integrin receptor.

Isoforms (3)

UniProt ID	Names	Canonical?
O75077-1	Alpha	yes
O75077-2	Beta
O75077-3	Gamma

RefSeq proteins (2): NP_001397914, NP_003803* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000742	EGF	Domain
IPR001590	Peptidase_M12B	Domain
IPR001762	Disintegrin_dom	Domain
IPR002870	Peptidase_M12B_N	Domain
IPR006586	ADAM_Cys-rich	Domain
IPR013111	EGF_extracell	Domain
IPR024079	MetalloPept_cat_dom_sf	Homologous_superfamily
IPR034027	Reprolysin_adamalysin	Domain
IPR036436	Disintegrin_dom_sf	Homologous_superfamily

Pfam: PF00200, PF01421, PF01562, PF07974, PF08516

UniProt features (31 total): glycosylation site 8, disulfide bond 7, domain 3, region of interest 2, compositionally biased region 2, splice variant 2, topological domain 2, signal peptide 1, propeptide 1, chain 1, mutagenesis site 1, transmembrane region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O75077-F1	76.38	0.48

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (7): 408–491, 450–475, 452–459, 560–580, 736–751, 745–757, 759–768

Glycosylation sites (8): 76, 96, 100, 263, 547, 548, 664, 732

Mutagenesis-validated functional residues (1):

Position	Phenotype
566	significantly lower of adhesion-promoting activity.

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-5682910	LGI-ADAM interactions
R-HSA-1266738	Developmental Biology

MSigDB gene sets: 190 (showing top): GOMF_METALLOPEPTIDASE_ACTIVITY, GOBP_RESPONSE_TO_PEPTIDE, TAKADA_GASTRIC_CANCER_COPY_NUMBER_DN, MEF2_02, AP2_Q3, MODULE_205, ONKEN_UVEAL_MELANOMA_UP, IRF1_Q6, MODULE_210, SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_DN, CORRE_MULTIPLE_MYELOMA_UP, HFH3_01, TSENG_IRS1_TARGETS_DN, RICKMAN_HEAD_AND_NECK_CANCER_A, DODD_NASOPHARYNGEAL_CARCINOMA_UP

GO Biological Process (4): proteolysis (GO:0006508), cell adhesion (GO:0007155), central nervous system development (GO:0007417), cellular response to leukemia inhibitory factor (GO:1990830)

GO Molecular Function (4): metalloendopeptidase activity (GO:0004222), integrin binding (GO:0005178), metallopeptidase activity (GO:0008237), protein binding (GO:0005515)

GO Cellular Component (6): extracellular region (GO:0005576), plasma membrane (GO:0005886), presynaptic membrane (GO:0042734), glutamatergic synapse (GO:0098978), endomembrane system (GO:0012505), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Developmental Biology	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
protein metabolic process	1
cellular process	1
nervous system development	1
system development	1
cellular response to cytokine stimulus	1
response to leukemia inhibitory factor	1
endopeptidase activity	1
metallopeptidase activity	1
signaling receptor binding	1
protein-containing complex binding	1
cell adhesion molecule binding	1
peptidase activity	1
binding	1
membrane	1
cell periphery	1
synaptic membrane	1
presynapse	1
synapse	1
vacuole	1
plasma membrane	1

Protein interactions and networks

STRING

980 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ADAM23	LGI1	O95970	996
ADAM23	ADAM22	Q9P0K1	896
ADAM23	LGI3	Q8N145	850
ADAM23	LGI2	Q8N0V4	730
ADAM23	KCNA1	Q09470	692
ADAM23	DLG4	P78352	597
ADAM23	LGI4	Q8N135	590
ADAM23	MLF1	P58340	542
ADAM23	ERV3-1	Q14264	519
ADAM23	ERVFRD-1	P60508	517
ADAM23	PRDM5	Q9NQX1	515
ADAM23	CNTNAP2	Q9UHC6	507
ADAM23	DLG2	Q15700	500
ADAM23	CACNG2	Q9Y698	461
ADAM23	ZDBF2	Q9HCK1	453

IntAct

8 interactions, top by confidence:

A	B	Type	Score
FBXO2	TMEM131L	psi-mi:“MI:0914”(association)	0.530
ADAM23	YWHAZ	psi-mi:“MI:0915”(physical association)	0.370
CANX	HLA-A	psi-mi:“MI:0914”(association)	0.350
ADAM11	ADAM23	psi-mi:“MI:0914”(association)	0.350
KLHL22	TRAV18	psi-mi:“MI:0914”(association)	0.350
DISC1	ADAM23	psi-mi:“MI:0915”(physical association)	0.000
DYRK1A	ADAM23	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (9): ADAM23 (Affinity Capture-MS), ADAM23 (Affinity Capture-MS), ADAM23 (Affinity Capture-MS), ADAM23 (Two-hybrid), ADAM23 (Cross-Linking-MS (XL-MS)), ADAM23 (Affinity Capture-MS), ADAM23 (Affinity Capture-MS), ADAM23 (Affinity Capture-MS), ADAM23 (Affinity Capture-RNA)

ESM2 similar proteins: A2A259, A2AIR5, H2Q5A1, O00222, O15399, O60242, O75077, O75882, O97741, P15209, P24786, P31423, P35400, P37088, P47743, P55270, P70579, Q00961, Q01098, Q03351, Q03391, Q13507, Q14833, Q14957, Q16288, Q1ZZH0, Q4R766, Q5IS37, Q5RDQ8, Q62645, Q63604, Q68ED2, Q68EF4, Q6AYT7, Q80ZF8, Q8CIW5, Q8TCU5, Q8VHN2, Q91044, Q91YD4

Diamond homologs: A0A0B4U9L8, A0A6B7FMR5, A2CJE2, A2CJE3, A2CJE4, A3R0T9, A4PBQ9, A8QL48, A8QL49, A8QL59, B8K1W0, C0LZJ5, C5H5D1, C5H5D2, C5H5D3, C5H5D4, C5H5D5, C5H5D6, C9E1R8, C9E1S0, D3TTC1, D3TTC2, D5LMJ3, D6PXE8, D8VNS0, F8RKV9, F8RKW0, F8RKW1, F8S108, G5EFD5, J3S829, J3S830, J3SDW6, J3SDW8, O35227, O35674, O42138, O75077, O93517, O93518

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

119 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	1
Uncertain significance	88
Likely benign	12
Benign	2

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
59163	GRCh38/hg38 2q33.3(chr2:206391900-207078994)x3	Pathogenic
150331	GRCh38/hg38 2q33.3(chr2:205163962-206491669)x4	Likely pathogenic

SpliceAI

5113 predictions. Top by Δscore:

Variant	Effect	Δscore
2:206445469:A:T	donor_gain	1.0000
2:206479799:GATT:G	donor_gain	1.0000
2:206481221:T:A	acceptor_gain	1.0000
2:206481227:CATA:C	acceptor_loss	1.0000
2:206481228:ATAG:A	acceptor_gain	1.0000
2:206481229:T:G	acceptor_gain	1.0000
2:206481229:TA:T	acceptor_loss	1.0000
2:206481230:A:AG	acceptor_gain	1.0000
2:206481230:A:T	acceptor_loss	1.0000
2:206481230:AG:A	acceptor_gain	1.0000
2:206481231:G:A	acceptor_loss	1.0000
2:206481231:G:GA	acceptor_gain	1.0000
2:206481231:GG:G	acceptor_gain	1.0000
2:206481231:GGCT:G	acceptor_gain	1.0000
2:206481304:AACAA:A	donor_gain	1.0000
2:206481305:ACAA:A	donor_gain	1.0000
2:206481306:CAA:C	donor_gain	1.0000
2:206481307:AA:A	donor_gain	1.0000
2:206481308:AGTG:A	donor_loss	1.0000
2:206481309:G:C	donor_loss	1.0000
2:206481309:G:GG	donor_gain	1.0000
2:206481310:TGAG:T	donor_loss	1.0000
2:206530883:A:AG	acceptor_gain	1.0000
2:206530883:AGT:A	acceptor_gain	1.0000
2:206530884:G:GA	acceptor_gain	1.0000
2:206530884:GT:G	acceptor_gain	1.0000
2:206530884:GTG:G	acceptor_gain	1.0000
2:206542135:G:GG	donor_gain	1.0000
2:206543251:A:AG	acceptor_gain	1.0000
2:206543251:AGT:A	acceptor_gain	1.0000

AlphaMissense

5502 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:206567243:T:G	F472C	1.000
2:206594891:T:A	C745S	1.000
2:206594892:G:C	C745S	1.000
2:206596105:T:A	C768S	1.000
2:206596106:G:A	C768Y	1.000
2:206596106:G:C	C768S	1.000
2:206596107:C:G	C768W	1.000
2:206609937:G:A	G796D	1.000
2:206609946:C:A	A799D	1.000
2:206609948:G:C	G800R	1.000
2:206609949:G:A	G800D	1.000
2:206609958:T:A	L803Q	1.000
2:206609967:C:A	A806D	1.000
2:206609976:T:A	L809H	1.000
2:206609979:G:A	G810E	1.000
2:206542064:T:C	C196R	0.999
2:206542066:T:G	C196W	0.999
2:206550135:T:C	L303P	0.999
2:206559994:G:C	A349P	0.999
2:206560006:T:A	W353R	0.999
2:206560006:T:C	W353R	0.999
2:206560008:G:C	W353C	0.999
2:206560008:G:T	W353C	0.999
2:206560112:T:C	L388P	0.999
2:206565049:T:A	C459S	0.999
2:206565049:T:C	C459R	0.999
2:206565050:G:C	C459S	0.999
2:206567242:T:C	F472L	0.999
2:206567243:T:C	F472S	0.999
2:206567244:T:A	F472L	0.999

dbSNP variants (sampled 300 via entrez): RS1000002980 (2:206483157 A>G), RS1000006541 (2:206500604 C>T), RS1000029130 (2:206615308 G>A,C,T), RS1000032401 (2:206613839 T>G), RS1000033702 (2:206604582 C>T), RS1000058837 (2:206447588 A>G,T), RS1000062555 (2:206490824 C>G), RS1000075001 (2:206499525 A>C,G), RS1000088343 (2:206619516 C>A,G), RS1000112296 (2:206578072 A>G), RS1000116967 (2:206449596 C>T), RS1000117970 (2:206491348 A>G), RS1000122734 (2:206569702 A>G), RS1000129084 (2:206600196 T>C), RS1000146731 (2:206495629 G>A,C)

Disease associations

OMIM: gene MIM:603710 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — M12: Astacin/Adamalysin

CTD chemical–gene interactions

24 total (human), top 24 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	decreases expression, increases methylation	2
Tretinoin	decreases expression	2
Aflatoxin B1	decreases methylation	2
bisphenol A	increases methylation	1
terbufos	increases methylation	1
cinnamaldehyde	increases expression	1
sodium arsenite	decreases expression	1
cobaltous chloride	decreases expression	1
benzo(e)pyrene	increases methylation	1
abrine	decreases expression	1
jinfukang	affects cotreatment, increases expression	1
Temozolomide	decreases expression	1
Troglitazone	increases expression	1
Atrazine	increases expression	1
Cisplatin	affects cotreatment, increases expression	1
Diethylhexyl Phthalate	decreases expression	1
Fonofos	increases methylation	1
Estradiol	affects cotreatment, increases expression	1
Methapyrilene	increases methylation	1
Parathion	increases methylation	1
Tobacco Smoke Pollution	increases expression	1
Triclosan	decreases expression	1
Valproic Acid	decreases expression	1
Aflatoxin M1	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.